Lanzafen

Olanzapine, the active ingredient in Lanzafen, is an atypical antipsychotic presented as an oral tablet for oral use. It is prescribed for the management of schizophrenia and bipolar disorder in adult patients, helping to control psychotic symptoms and mood swings.

GNH USA supplies Lanzafen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Lanzafen (olanzapine) acts on dopamine and serotonin pathways to treat serious psychiatric conditions.

Schizophrenia: reduces positive and negative symptoms and improves overall functioning. Bipolar I disorder (manic episodes): controls acute mania and stabilises mood. Bipolar disorder maintenance: helps prevent recurrence of manic or depressive episodes.

Common Side Effects: - Weight gain: increased appetite leading to gradual weight increase. - Sedation: drowsiness or feeling unusually tired. - Dry mouth: reduced salivation causing discomfort. - Constipation: slowed gastrointestinal motility. - Dizziness: light‑headedness, especially when standing. - Increased appetite: heightened desire for food.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis or leukopenia: severe reduction in white blood cells. - Tardive dyskinesia: involuntary, repetitive movements. - Severe hyperglycaemia: marked increase in blood glucose levels. - Seizures: risk of convulsive episodes. - Cardiac arrhythmias: abnormal heart rhythms.

Before initiating therapy, clinicians should consider several safety measures.

Monitor metabolic parameters: regularly check weight, glucose, and lipid levels. Assess cardiovascular risk: evaluate blood pressure and heart function. Screen for seizure history: avoid use in patients with uncontrolled epilepsy. Use caution in elderly with dementia: increased mortality risk has been reported. Avoid abrupt discontinuation: taper gradually to reduce withdrawal effects. Store at ambient temperature: keep in the original pack, protect from moisture.

Olanzapine may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, reducing olanzapine levels. - Fluvoxamine: inhibits metabolism, increasing olanzapine exposure. - Smoking: induces CYP1A2, lowering drug concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect. - Lithium: potential for increased neurotoxicity. - Anticholinergics: heightened anticholinergic side‑effects.